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Abstract 
The ability to produce rapid, cost-effective and human-relevant data has the potential to accelerate the 
development of new drug delivery systems. Intraocular drug delivery is an area undergoing rapid expansion, 
due to the increase in sight-threatening diseases linked to increasing age and lifestyle factors. The outer blood-
retinal barrier (OBRB) is important in this area of drug delivery, as it separates the eye from the systemic blood 
flow. This study reports the development of complementary in vitro and in silico models to study drug transport 
from silicone oil across the outer blood-retinal barrier. Monolayer cultures of a human retinal pigmented 
epithelium cell line, ARPE-19, were added to chambers and exposed to a controlled flow to simulate drug 
clearance across the OBRB. Movement of dextran molecules, and release of ibuprofen from silicone oil in this 
model were measured. Corresponding simulations were developed using COMSOL Multiphysics 
computational fluid dynamics (CFD) software and validated using independent in vitro data sets. 
Computational simulations were able to predict dextran movement and ibuprofen release, with all of the 
features of the experimental release profiles being observed in the simulated data. Simulated values for peak 
concentrations of permeated dextran and ibuprofen released from silicone oil were within 18% of the in vitro 
results. This model could be used as a predictive tool of drug transport across this important tissue.  
  
 
 
  
 3 
Introduction 1 
The ability to produce models that mimic tissue biology and physiology is crucial in the development of drug 2 
delivery systems. Currently, much of the pre-clinical work is conducted in animals, the limitations of which 3 
are well-reported and which may be the cause of the 86% of drugs that fail in clinical testing (1). The use of 4 
in vitro models means that human tissue can be used, minimising species differences as well as ethical 5 
concerns. Although lacking the complex environment of a living body, they can be used to generate reliable 6 
data on drug transport and toxicology (2-4). Computer science and simulation of pharmacokinetic behaviour 7 
is becoming an integral part of pharmaceutical research and development due to the significant reductions in 8 
cost and time they can offer. In silico tools can, in conjunction with complementary empirical measurements, 9 
contribute to the optimisation of novel drug delivery systems, and ever-increasing computing power has 10 
allowed more sophisticated models to be developed. The combination of accurate, validated in vitro and in 11 
silico models has the potential to revolutionise the development of drug delivery technologies by providing 12 
rapid, reproducible and human-relevant data (5). 13 
Epithelial barriers are particularly important in drug delivery, as one of the primary functions of epithelium is 14 
to act as a barrier, and certain drugs must cross the barrier to reach the target tissue. Tissues such as skin (6), 15 
intestinal (7) and pulmonary epithelium (8) have all been studied in the development of drugs and chemicals, 16 
and the complexity of the models of these barriers has improved dramatically in the last few decades, from 17 
simple two-dimensional, multi-well plate cultures to intricate microfluidic culture chips. Many epithelial 18 
barrier models, such as those for skin, are based on an air-liquid interface,. In the case of fluid-fluid 19 
interfaces, many are designed as static culture systems. These static culture systems allow the determination 20 
of parameters such as barrier permeability and diffusion coefficients, which are of crucial importance when 21 
studying the movement of potential therapeutic treatments across epithelial tissues. They do not, however, 22 
provide realistic, time-dependant development of concentration gradients across the model as they do not 23 
mimic the many dynamic factors associated with these physiological barriers. With the rapid rise in 24 
microfluidic technologies for cell culture that has occurred over recent years, the creation of dynamic in vitro 25 
models has become more accessible (9). 26 
There are many eye diseases that require treatment with pharmacological agents. In contrast to the front of 27 
the eye, where drug delivery can often be achieved by topical application of eye drops and ointments, many 28 
eye diseases of the posterior segment of the eye require the delivery of drugs directly into the vitreous. The 29 
drugs may be required to treat acute infection or inflammation, or to treat a chronic condition such as age-30 
related macular degeneration or diabetic retinopathy. In the latter case, repeated intravitreal injection or use 31 
of implantable drug delivery devices are the preferred methods to achieve therapeutic levels of drug over the 32 
extended periods required. Due to the cost and invasive nature associated with repeated intravitreal injection, 33 
as well as the potential for sight-threatening complications, much effort has been directed towards 34 
developing implants that can deliver drugs over extended periods (10). We have recently developed 35 
technology to achieve extended release of drugs from silicone oil tamponades (11, 12). Silicone oil and gas 36 
tamponades are used to replace the native vitreous humour in the treatment of sight-threatening retinal 37 
  
detachments. They inhibit the flow of aqueous fluids into the subretinal space, exclude inflammatory factors, 38 
and support the retina as tears heal (13, 14).  Silicone oils are the only medical devices licenced for long-term 39 
use as tamponades. Drug release from silicone oil tamponades would release pharmacological adjuncts to the 40 
surgical treatment with the aim of reduce complications caused by scarring conditions such as proliferative 41 
vitreoretinopathy and proliferative diabetic retinopathy. The ability to predict the release of drugs from such 42 
devices, as well as understand factors that influence clearance from the posterior cavity, is crucial if over- 43 
and under-dosing is to be avoided. 44 
Drugs administered intravitreally, whether via injection or an implant, are cleared via two routes, either 45 
anteriorly or posteriorly (Figure 1A). Nearly all compounds can be eliminated via the anterior route. 46 
Anteriorly, once the drug has diffused across the vitreous, it enters the aqueous of the posterior chamber 47 
where it is transported into the anterior chamber and cleared, either through the Schlemm’s canal or into the 48 
uveal blood flow (15). Alternatively, posterior elimination occurs through permeation across the posterior 49 
blood-ocular barriers such as the outer and inner blood-retinal-barrier (BRB). This route requires either 50 
adequate passive permeability of agents, which is generally only applicable to very low molecular weight or 51 
lipophilic substances, or active transport of molecules by the cells present in the barrier. For this reason, 52 
larger or hydrophilic molecules generally have longer half-lives in the vitreous as they are not able to move 53 
as freely through the vitreous or pass across the retina (16).  54 
In vitro models have often been used to investigate the permeability of drugs and compounds across the 55 
retinal pigmented epithelium (RPE) or to model diseases of the outer blood-retinal barrier (OBRB). In order 56 
to obtain a physically accurate model of the OBRB, the main anatomical structures (retinal pigment 57 
epithelium, Bruch’s membrane and choroid), as well as physiological conditions, such as flow, need to be 58 
incorporated. Although many of the in vitro models of the OBRB that have been reported include the main 59 
anatomical structures within the tissue (17-20), few include a flow mechanism to model the blood flow 60 
within the choroid and to avoid the formation of an unstirred water layer (21). This flow mechanism is 61 
particularly important when investigating the clearance of drugs across the BRB, as it causes systemic 62 
removal of drugs. Yeste et al. describe a system which comprises the co-culture of human retinal endothelial 63 
cells and ARPE-19 (a widely-used RPE cell line (22, 23)) in a microfluidic culture system (24). This system 64 
compartmentalises the cells and, therefore, does not create a single construct. The transepithelial electrical 65 
resistance of each of the cell layers was measured independently; this does not represent the true barrier 66 
functionality of the tissue as it investigates each component of the barrier in separate parts. Additionally, no 67 
investigations of drug transport across the barrier were conducted. Another microfluidic chip device was 68 
reported by Chen et al. who investigated the co-culture of ARPE-19s and human vascular endothelial cells 69 
(HUVECs) in a microfluidic model of choroidal angiogenesis (25). Within this model, glucose was 70 
transported to the cells within the flow of the media but the movement of the molecules was not studied. The 71 
lack of studies regarding in vitro modelling of the effects of posterior systemic clearance of drugs in the eye 72 
by, for example, incorporating flow, leaves scope for this to be investigated further.  73 
  
The Kirkstall QV600 cell culture chamber is a novel system which has been designed to allow cells to be 74 
cultured in an air-liquid interface environment in vivo, for example skin, respiratory epithelium or corneal 75 
cells. It can also be modified to co-culture cells at a fluid-fluid interface and expose each surface to 76 
independently controlled flow. The availability of published data from studies using this system is limited. 77 
The QV600 has been used to study permeability of fluorescein across a cell culture model of gut epithelium 78 
(26), demonstrating that the application of flow resulted in increased permeability, as well as increased 79 
barrier function of the cells. It has also been used to build a human bronchial or small airway epithelial 80 
model, using the combination of the air-liquid interface and flow to improve and accelerate cell 81 
differentiation (27). To the best of our knowledge, there are no reports of this chamber being used to build a 82 
model of the OBRB. For the purposes of investigating drug permeability across the OBRB, this system 83 
provides many of the necessary properties for a representative model, i.e. the ability to mimic clearance by 84 
choroidal flow and to incorporate drug delivery devices that work in aqueous and non-aqueous environments 85 
(Figure 1B).   86 
There have been several studies carried out that specifically use computational techniques to model drug 87 
delivery and kinetics in the posterior segment of the eye, including systemic delivery methods, intravitreal 88 
injection and ocular implants (28-30). These models all simulate drug delivery within computer-built 89 
geometries of the eye and although they can provide useful information regarding the drug kinetics in the 90 
eye, experimentally these results cannot be validated in vivo due to the invasive nature of the techniques that 91 
would be required to do so. Much of the work carried out is based on experimental work conducted almost 92 
four decades ago by Palestine and Brubaker who investigated the kinetics of fluorescein in the human eye 93 
(31). Other published pharmacokinetic data is predominantly from animal models, which brings a series of 94 
well-reported problems, including the use of different animal models, differences between animal and human 95 
anatomy and vitreous composition, and different experimental setups (32). In order for the sophistication of 96 
these models of drug delivery in the eye to be improved, more experimental data is required to provide a 97 
greater database for finite element analysis validation. Furthermore, very little data on the release of drugs 98 
from silicone oil tamponades is available. For this reason, it could be useful to build predictive models of in 99 
vitro devices used in the development of novel drug delivery devices as they are able to be validated using 100 
data from benchtop experiments. Although these models may not provide an approximation of what will 101 
occur once the device is administered in the eye, it may make the development process more efficient. In 102 
addition, an accurate model of drug transport across the outer blood-retinal barrier may be able to help 103 
predict systemic effects from ocular delivery, or design drugs that could be delivered systemically and cross 104 
the blood-retinal barrier (33). In this study we used a combinatory approach of in vitro and in silico 105 
modelling to investigate drug transport and clearance through the posterior drug elimination pathway with 106 
the aim of producing validated tools for the optimisation of intravitreal drug delivery devices.  107 
 108 
  109 
  
Materials and Methods 110 
In vitro model 111 
Materials 112 
Fluorescein isothiocynate conjugated dextran (FD) was purchased from Sigma-Aldrich (FD-4, MW 4kDa) 113 
and diluted to 50µg/ml in phosphate-buffered saline (PBS) solution. Ibuprofen (2-(4-Isobutylphenyl) 114 
propionic Acid, C13H18O2, MW 206.29) was purchased from Tokyo Chemical Industry UK (I0415) and 115 
1mg/ml was dissolved in technical grade 1000 cSt silicone oil (SIO) obtained from Fluoron GmbH. PBS 116 
tablets were purchased from Thermo Scientific (Oxoid BR0014G) and used as instructed, 1 tablet per 100ml 117 
distilled water. Expanded-polytetrafluoroethylene (ePTFE_M) cell culture membrane inserts were purchased 118 
from Merck Millipore (PICM02150, 0.4µm pore size). The microfluidic chambers and associated silicone 119 
tubing were QV600 cell culture kits purchased from Kirkstall Ltd (Rotherham, UK) and the peristaltic pump 120 
(Parker, PF22X0103) used to generate the fluid flow was also purchased from Kirkstall Ltd. Fluorescence 121 
measurements were performed using a microplate reader (FLUOstar OPTIMA, BMG LABTECH). UV–122 
visible spectroscopy (UV–vis) measurements were performed in UV transparent, plastic cuvettes (Merck 123 
Z605050) using a spectrometer (SPECTROstar nano, BMG LABTECH).  124 
Methods 125 
Cell culture 126 
ARPE-19 cells (ATCC® Number: CRL-2302™) between passage 23-30 were cultured in Dulbecco’s 127 
Modified Eagle Medium/Ham’s Nutrient Mixture F-12 Formulation (1:1 mix) with L-Glutamine, 15mM 128 
HEPES and sodium bicarbonate (DMEM-F12) (Sigma, D8437) supplemented with 10% fetal bovine serum 129 
(FBS) (BioSera, S1900) and 1% Penicillin/Streptomycin (Sigma, P0781). Following seeding, cells were 130 
maintained in 2% serum. Cells were seeded on ammonia plasma-treated ePTFE_M cell culture insert 131 
membranes, (NH3_ePTFE_M). These are ePTFE membranes that have been subjected to a proprietary 132 
treatment by the manufacturer, designated ePTFE_M, and ammonia gas plasma treated to improve the 133 
hydrophilicity of the membrane as described previously (34, 35) designated NH3_ePTFE_M. Following 134 
seeding cells were cultured for 10 days at 37˚C in a humidified incubator with 5% CO2. 135 
Determination of apparent permeability coefficient 136 
Permeability experiments were performed in a classic two-compartment, zero-flow, model system. 137 
NH3_ePTFE_M cell culture inserts were placed in a 24 well plate and 400µl of tracer molecule solution 138 
(50µg/ml FITC-dextran; (MW: 4 kDa) was added to the donor compartment with 600µl of PBS solution in 139 
the receptor compartment. In static conditions, transmembrane flux (Jd) is predominantly determined by 140 
diffusive forces and can thus be calculated using the permeability (Ps) and concentration gradient (∆C): 141 
Jd=Ps ∆C 142 
  
At time intervals of 1, 3, 8 and 24hr, 50µl samples were taken from the receptor compartment and replaced 143 
with fresh PBS solution. Samples were stored at 4⁰C and protected from light until the time points had been 144 
completed, and the fluorescence intensity of the samples was read in a microplate reader at λex (excitation 145 
wavelength): 485nm, λem (emission wavelength): 535nm. Flux was determined from the slope of the linear 146 
portion of the curve. Calibration curves (R2≥0.997) for each molecule were made using a serial dilution of 147 
50µg/ml dextran solution. Average measurements for blanks (0µg/ml of dextran) were subtracted from the 148 
standards and the unknown samples. Concentrations of the unknown samples were determined from the 149 
calibration curves and each sample was repeated in triplicate (n=3). 150 
Measurement of drug release 151 
An experimental concentration of 1mg of ibuprofen (ibu) in 1ml of 1000c.st silicone oil (Fluoron GmbH) 152 
was used. The ibu-SiO was stirred for 72 hours in a sealed flask and then filtered in a Class II biological 153 
safety hood to sterilise. In a 24-well plate, 1mL of ibu-SiO was syringed on top of 500µl of PBS. At defined 154 
time points, 100µl samples were taken from the PBS, transferred to UV transparent cuvettes (UVette, 155 
Eppendorf) and the time-dependent increase in ibuprofen concentration measured by UV-Vis spectroscopy 156 
(n=3). 157 
Determination of Diffusion coefficients 158 
The diffusion coefficients (D) were calculated using the Stokes-Einstein equation, using the appropriate 159 
solvent viscosity for either DMEM-F12, PBS, water or SiO (µ), the apparent radius (r) of either the dextran 160 
or ibuprofen molecule (36), temperature (T) and Boltzmann constant (k): 161 
D=kT/6πμr 162 
Drug clearance study  163 
The Kirkstall QV600 system was arranged in a single-pass series fluid circuit using a peristaltic pump to 164 
control the fluid flow inlet rate (Figure 1C). Either acellular or cell-seeded cell culture inserts containing 165 
400µl of tracer solution were inserted into the QV600 chamber to allow flow across the receptor side of the 166 
membrane. The cell culture inserts have a smaller diameter than the QV600 chamber. In order to create a 167 
seal between the donor and receptor compartments, a silicone O-ring was placed around the exterior wall of 168 
the insert before it was placed in the chamber. The system was incubated at 37⁰C and phosphate buffered 169 
saline solution was perfused through the receptor chamber at a constant flow rate for 24 hours (8 hours for 170 
2ml/min experiments). The flow rates used were 20µl/min, 200µl/min, 400µl/min.  171 
FITC-conjugated dextran (4kDa) was dissolved in DMEM-F-12 supplemented with 10% foetal calf serum to 172 
50µg/ml in the donor chamber. The systems were set up and perfused for 1hr, after which the flow was 173 
stopped and the tubes were clamped. The solution in the receptor chamber was completely removed and 174 
homogenised, and 50μl samples were taken. The systems were cleaned and reset, and the protocol was 175 
repeated for increasing periods of time (1hr time increments). The fluorescence intensity of the samples was 176 
  
read in a microplate reader at λex: 485nm, λem: 535nm. Concentration of the unknown samples was 177 
determined from the calibration curves and each sample was repeated in triplicate (n=3). 178 
Measurement of ibuprofen release from silicone oil under flow conditions 179 
The QV600 chamber and peristaltic pump were assembled as described previously. The system was primed 180 
with 30mL of sterile PBS. 2mL of 1mg/mL ibu-SiO was added directly on top of the PBS. The system was 181 
incubated at 37⁰C and PBS was perfused through the receptor chamber at a constant flow rate for 24 hours (8 182 
hours for 2ml/min experiments). The flow rates used were 20µl/min, 200µl/min and 2ml/min. At set time 183 
intervals, the ports were clamped shut and the volume of PBS beneath the ibu-SiO removed using a 25-gauge 184 
needle. A 25G needle allows the PBS to be removed but the viscosity of the oil prevents its withdrawal 185 
through the needle. The solution was homogenised and 50µL samples taken. UV-Vis was used to determine 186 
the ibuprofen concentration in the samples as previously described. 187 
Computer Model 188 
Geometry of the QV600 chamber and grid generation 189 
Figure 2 shows the 2-dimensional geometrical models used. Key dimensions are based on dimensions 190 
obtained from the technical drawing from the QV600 chamber. Differences in the donor compartment 191 
domain take into account the differences in geometry between the cell culture inserts (Figure 2A-D) and the 192 
silicone oil tamponade (Figure 2E, F). The cell culture inserts have a smaller diameter than the chamber, 193 
therefore the width of this domain is reduced. Additionally, the geometry used in the dextran transport 194 
studies included a third domain representative of the ePTFE/cell membrane. The dimensions of this domain 195 
were dependent on whether a representative cell monolayer was included. 196 
The mesh was generated using the commercial software, COMSOL Multiphysics. For the single phase, 197 
dextran transport studies, the mesh comprised free triangular elements with boundary layers at the no slip 198 
walls. The total number of elements in the mesh was 38267. For the ibuprofen release studies the mesh 199 
consisted of 2258 free triangular elements in a moving mesh system to model the flow of two immiscible 200 
liquids.  201 
Governing equations 202 
The incompressible Navier-Stokes equations along with a species transport equation were solved in order to 203 
obtain the velocity and concentration fields across the models. 204 
Momentum equation: 205 
𝜌 (
𝜕𝒖
𝜕𝑡
+ 𝒖. ∇𝒖) =  −∇p +  ∇. 𝐓 + 𝐟 206 
The left-hand side of the equation describes the product of the density of the fluid, ρ, and the acceleration 207 
that is experienced by the particles within the fluid where u is the velocity vector. The right-hand side of the 208 
  
equation incorporates the forces which are responsible for the particle acceleration, the pressure, p; the 209 
viscous shear stresses, T; and volume forces, f, which is equal to the product of the gravity constant, g, and 210 
the density of the fluid. 211 
Continuity equation: 212 
∇. 𝒖 = 0 213 
Species transport equation:  214 
𝜕𝑐𝑖
𝜕𝑡
+ ∇. (−𝐷∇𝑐𝑖) + 𝒖 . ∇𝑐𝑖 =  0 215 
This equation solves the mass conservation equation for the concentration of one or more chemical species, 216 
ci.. The diffusion coefficient, D, which was determined from the in vitro studies, is specific to each species. 217 
These are presented in Table 1. As the drugs used in this study are not reacting with the cells and the cell 218 
layer acts only as a barrier, the right-hand side of the equation is zero.  219 
Two models were investigated in this study: one to study the passage of dextran molecules across the 220 
NH3_ePTFE_M membrane and the other to study the release of ibuprofen from silicone oil. These two 221 
models are described separately below.  222 
Dextran Transport Model 223 
The model itself consists of two parts: a laminar flow interface to compute the velocity flow and pressure 224 
fields of the single-phase fluid flow, and a transport of diluted species interface. COMSOL provides this 225 
interface to calculate the concentration field of a dilute solute in a solvent, i.e. the fluorescently labelled 226 
dextran solutions diluted in culture medium. The model was run to simulate both the absence and presence of 227 
cells using alterations in both the geometry and permeability boundary conditions that are described below. 228 
An additional physics node was included to model the transport of FD through the membrane into basolateral 229 
medium flow. This model accounts for the dissipation of kinetic energy experienced by the fluid moving 230 
through a porous matrix through means of viscous shear. In COMSOL, this is implemented using the fluid 231 
and matrix properties node which uses the Brinkman equations: 232 
−
𝜇
𝜅
𝒖 +  
𝜇
𝜀𝑝
∇2𝒖 =  ∇p 233 
where κ is the permeability of the membrane to the fluid and εp is the porosity (Table 1). This node was only 234 
applicable to the membrane part of the model and were therefore only applied to that domain.  235 
Boundary Conditions 236 
A no slip boundary condition was applied to the walls of the geometry:  237 
𝒗 = 0 238 
  
The inlet was applied to the left-hand wall of the inlet tube. The velocity field, v, for the inlet was defined 239 
by: 240 
𝒗 =  𝑄/𝐴 241 
where Q is the flow rate and A is the cross-sectional area of the inlet tube. A range of inlet flow rates was 242 
investigated to coincide with the flow rates used in the in vitro experiments: 20µL/min, 200µL/min, 243 
400µL/min, and 2mL/min. The outlet was applied to the right-hand wall of the outlet tube. The outlet 244 
condition was a zero pressure (p) condition: 245 
p = 0 246 
Two transport of diluted species nodes were used in the transport of dextran simulations: one for the donor 247 
and receptor domains, and one for the membrane domain. This separate node for the membrane domain 248 
allowed the difference in diffusion in that domain to be accounted for. 249 
For the donor and receptor domains, a no flux boundary condition was applied to the exterior boundaries of 250 
the geometry on the same edges as the no slip conditions for laminar flow. An outflow condition was applied 251 
to the outlet to account for transport of FD out of the domain by the fluid motion. At the boundaries where 252 
the two domains meet the membrane domain, a pointwise constraint was applied to compute the transfer of 253 
mass across the membrane out of the donor domain into the receptor domain. The pointwise constraint was a 254 
function of the two concentrations at the boundaries which were defined by the diffusive and convective 255 
movements of the FD through the domains. The flux (Jd) across the boundaries was computed based on the 256 
concentration of FD (ci) and the diffusion coefficient (D) for each domain.  257 
𝐽𝑑 =  −𝐷∇𝑐𝑖 + 𝒖𝑐𝑖 258 
The second transport of diluted species node applied similar boundary conditions as above but across the 259 
membrane domain, therefore accounting for the difference in diffusion. A no flux condition was applied on 260 
the exterior wall boundaries of the membrane. The same function for the pointwise constraint was applied to 261 
the boundaries that were shared with the other two domains. The dimensions of the membrane domain were 262 
altered depending on whether the presence of the cells was being modelled or not. In the presence of cells, 263 
the membrane domain was 70µm in height and the appropriate diffusion coefficient of the domain was used, 264 
as described in Table 1. In the absence of the cells, the domain was reduced to 50µm and the diffusion 265 
coefficient was altered to account for their absence. 266 
Ibuprofen Release Model 267 
The second model explored ibuprofen release from SiO. With the differences that the ibuprofen release 268 
studies required, the model was altered to simulate the interaction of two immiscible fluid phases: the 269 
aqueous PBS phase and the 1000 c.st silicone oil phase. This model also removes the membrane domain as 270 
the movement of drug was directly from the oil into PBS. 271 
  
To model the two-phase nature of the model, an additional moving mesh mechanism was used. The laminar 272 
flow moving mesh physics node in COMSOL solves the same equations for velocity and pressure fields, but 273 
also tracks the movement of the interface between two immiscible fluids by allowing deformation of the 274 
mesh during the solution. A free mesh deformation was prescribed to the domains either side of the interface. 275 
The inlet and outlet tubes of the geometry were prescribed a fixed mesh as only one of the fluid phases 276 
moved through these regions. The mesh is also prescribed zero displacement at the exterior boundary walls 277 
to prevent collapsing of the solid wall boundaries. The walls that were in contact with the fluid-fluid 278 
interface were prescribed free deformation of the mesh parallel to the exterior wall boundaries, but with zero 279 
perpendicular displacement, again to prevent collapse of the solid exterior walls. 280 
The additional equation solved for in the laminar flow moving mesh interface was the Navier slip equation. 281 
This condition was applied to the boundaries that were in contact with the fluid-fluid interface, and is 282 
appropriate for the two-phase flow model. This condition adds a frictional force, Ffr, at a stationary wall, 283 
which allows the interface to move against the wall. 284 
𝑭𝑓𝑟 =  −
𝜇
𝛽
𝒖 285 
where β is the slip length, which was a function of the element size of the mesh, μ is viscosity and u is the 286 
velocity vector. The fluid-fluid interface node also takes into account the interfacial tension of the two fluids, 287 
σ = 50mN/m (37), and the contact angle between the wall and the fluids, θw = 1.3 rad (38). 288 
Due to the nature of the two-phase model, a stationary solution for the velocity field could not be solved 289 
because of the movement at the interface, therefore a time-dependent solution was obtained over 9 seconds, 290 
at which point the flow stabilised. This stabilised flow was used as the velocity field input for the transport of 291 
diluted species solutions. 292 
The solution for the transport is simpler for the release of ibuprofen because the concentration species only 293 
moves through two domains and not the fluid matrix domain, therefore the movement is purely diffusion and 294 
convection in the two different fluids. An additional expression for the partition coefficient (Pp) is included 295 
in the mass transport between the two phases. 296 
𝐽𝑑 = −𝑃𝑠(𝑃𝑝𝑐𝑑 − 𝑐𝑟) 297 
where Jd is flux, Ps is permeability and cd and cr represent the concentration in the donor and receptor domain 298 
respectively. 299 
 300 
Boundary Conditions 301 
A no-slip condition was applied to the exterior boundary walls. The walls in contact with the fluid-fluid 302 
interface were assigned a Navier slip condition. This condition allows the fluid-fluid interface to move along 303 
  
the wall. Additionally, the top boundary of the oil phase, parallel to the fluid-fluid interface, was assigned a 304 
slip condition. This slip condition allows the deformation of the mesh to continue throughout the phase 305 
whilst still applying a no penetration condition, meaning the model allows the movement of the mesh 306 
without fluid leaving that domain. 307 
The inlet and outlet conditions were as described previously and the same flow rates were investigated as 308 
with the dextran transport studies (20µL/min, 200µL/min, 400µL/min and 2mL/min). A volume force was 309 
also implemented across the entire geometry to account for gravity in the system. 310 
Two transport of diluted species nodes were used to investigate the release of ibuprofen from the silicone oil: 311 
one for the oil phase and one for the aqueous phase. The appropriate diffusion coefficients (Table 1) were 312 
applied to each fluid domain and a pointwise constraint was applied at the fluid-fluid interface. This 313 
pointwise constraint takes into account the concentration at the interfaces and solves for the mass flux across 314 
that boundary using a function of the concentration gradient and the partition coefficient. The accepted error 315 
between the computer models and experimental data was set by two boundaries: <10% was considered to be 316 
good agreement and <20% was considered to be acceptable agreement.  317 
Material properties 318 
1000 c.st silicone oil is often used by surgeons because its viscosity makes it easily injectable, a motivation 319 
for its use in this study. SiO has a lower density than water, and therefore floats on it, but this oil has a higher 320 
viscosity. These properties are shown in Table 2. Rheological evaluation of water, PBS and silicone oil was 321 
done using a Rheosense Inc µVISC rheometer (Rheosense Inc., USA) with a 100N load cell. The results 322 
showed negligible differences between water and PBS in terms of viscosity and density, therefore water was 323 
used as the aqueous fluid of interest in the computer model. A handheld density meter (Anton Parr) was used 324 
to measure the density of the fluids at 37°C. 325 
Results and Discussion 326 
Grid Independence Studies 327 
To demonstrate grid independence, simulations were run with varying degrees of mesh refinement (dextran 328 
model between 18,000 and 108,814 elements, ibuprofen model between 300 and 4000 elements). The 329 
velocity at two points in the geometry was measured (Figure 2A, 2E) and compared as the mesh was refined. 330 
The number of elements used in each model was justified by using the mesh refined to within 5% agreement 331 
between both points and the highest resolved mesh (Figure 2G, H). This was chosen as an acceptable error 332 
limit that reduced the computational time whilst maintaining sufficient accuracy. For the dextran model, this 333 
was 38267 elements. For the ibuprofen model, this was 2258 elements. 334 
Dextran Transport Studies 335 
  
The predicted velocity profiles within the Kirkstall QV600 for flow rates 20, 200 and 400µL/min the 336 
velocity fields produce similar patterns (Figure 3): a parabolic flow out of the inlet tube and in to the outlet 337 
tube with considerably lower velocities in the main well of the chamber. Each flow rate shows areas of 338 
recirculating flow trapped in the corners of the receptor compartment on the inlet side, which increase in size 339 
as the inlet flow rate is increased. The streamlines show that, at the lowest flow rate (20µL/min), the flow in 340 
the main chamber has little effect on the velocity field in the donor compartment of the chamber. As the flow 341 
rate increases, the flow profile of the donor compartment becomes more uniform as fluid from the main well 342 
penetrates through the membrane and causes fluid flow in the donor compartment. This phenomenon is most 343 
obvious at the highest flow rate (2ml/min). In the donor compartment of this simulation, a complex flow 344 
regime is observed. The velocities in the main well of the chamber are also considerably higher than in 345 
comparison with lower inlet flow rates. Another feature of this high flow rate is the development of a 346 
dominating stream of fluid from the inlet tube to the outlet port and large area of recirculating fluid beneath 347 
this stream which occurs in the majority of the chamber volume. Previous studies have reported the flow rate 348 
within the choriocapillaris in vivo to be 9.45mL/hr or 160µL/min (39), and disruptions or alterations in the 349 
flow have been attributed to problems with homeostasis within the RPE (40, 41). Here, we wanted to 350 
investigate a range of flow rates, including one which was biologically relevant, in order to prove the 351 
reliability of the computer model. For this reason, flow rates which were experimentally achievable were 352 
used. Although 2mL/min was tested in the computer model and produced interesting flow patterns, this flow 353 
rate was found to be too high to maintain the survival of the ARPE-19 cells, therefore no further studies were 354 
conducted using this flow rate. 355 
To validate the numerical model, the results for concentration of dextran on the receptor compartment side of 356 
the membrane were compared with experimental data. Permeability and diffusion coefficients were 357 
determined in simple static experiments and implemented in the numerical model. The resulting coefficients 358 
(Table 1) were comparable with those seen in a similar experiment by Mannermaa et al. (19). In that study, 359 
the authors compared the transport of drugs through a static, ARPE-19-based model and bovine RPE tissue, 360 
finding similar transport trends. The simulation shows the concentration gradient of dextran in the donor 361 
compartment to decrease with increasing flow rate after 24 hours. As expected, dextran is less readily cleared 362 
across the barrier when the presence of cells is included in the simulation (Figure 4). The results of the model 363 
were then validated using data from complementary in vitro experiments. The numerical model shows 364 
agreement with the in vitro data in both the acellular and cell seeded experiments (Figure 5). At the higher 365 
flow rates, the simulated results are able to mirror the change in release exhibited in vitro, which shows a 366 
shift to a burst release response followed by an exponential decay in concentration over time, and there 367 
appears to be no correlation between flow rate and simulation accuracy (42).  The simulation of dextran 368 
transport was able to predict the maximum concentration (Cmax) observed in that chamber to within 5% of the 369 
acellular experimental data. The introduction of cells to the system increased the error observed in Cmax but 370 
still to within 18% of the experimental data. Similar studies, which simulated permeability of different 371 
molecular weight FITC-dextrans in a static set-up and across collagen or agarose gel, showed an increase in 372 
error (between approximately 4% and 46%) between their simulated and experimental results with increasing 373 
  
molecular weight (43). Here, we have only presented data for the transport of 4kDa FITC-dextran; other 374 
sizes were also investigated (40kDa and 70kDa FITC-dextran) with 4kDa and 40kDa producing similar 375 
errors, but 70kDa showed increased error in comparison. The simulation does not take into consideration the 376 
biological effects of culturing cells under flow might have on the barrier functionality of the ARPE-19 cell 377 
monolayer. There are studies which have investigated biological effects on epithelial tissues in computer 378 
simulations, for example modelling inflammatory effects on intestinal epithelium in necrotising enterocolitis 379 
(44), and investigating links between epithelial morphogenesis and cancer mutations (45). A combination of 380 
computational fluid dynamics modelling such as in this study and a more computational biology approach to 381 
investigate cell dependent changes in transport and clearance of molecules could further improve the 382 
agreement between the experimental and simulated data in cell seeded simulations.  383 
Ibuprofen Release Studies 384 
Tracking the fluid-fluid interface is important when considering the concentration distribution of drugs 385 
across the two fluids. An adaptive mesh was used to simulate the interaction between the silicone oil phase 386 
and the aqueous (PBS) phase. Based on the interfacial tension and wall contact angle of the two fluids, the 387 
simulation shows that a meniscus is formed between the two phases over time until a steady state is reached 388 
at approximately 1.4 seconds (Figure 6).  389 
In the two phase system (oil and aqueous), the simulation shows two distinct flow fields within each phase 390 
(Figure 7).  The flow field in the oil phase, however, does appear to be influenced by the flow rate of the 391 
aqueous phase. The flow fields formed at 20µL/min, 200µL/min and 400µL/min show similarities to those 392 
formed in the single phase, membrane system. At 20µL/min, however, the low flow rate inlet stream within 393 
the aqueous phase appears to bounce off the oil phase and creates a ripple within the primary flow stream.  394 
The interaction between the main flow stream and the oil phase also creates two recirculating streams within 395 
the oil domain itself. This phenomenon is observed for each of the flow rates studied, with the split in the 396 
two streams shifting towards the inlet as the inlet flow rate increased. Unlike the 2mL/min flow field in the 397 
single phase system, the 2mL/min flow profile for the two phase model did not develop large regions of 398 
recirculating flow and maintained a single dominating fluid stream from inlet to outlet. 399 
The concentration fields within the oil domain showed little difference as the flow rate increased, other than 400 
to shift the centre of diffusion either towards the inlet at 2mL/min. For each flow rate, the ibuprofen was 401 
never completely cleared from the oil domain by the final 72 hour time point. The simulation predicted that a 402 
small region of oil at the top of the domain, in contact with the exterior wall of the chamber through to the 403 
centre of the domain, maintained a low concentration of ibuprofen. 404 
To model the release of ibuprofen from SiO, the physics controls of the computer model was redesigned to 405 
allow the interaction of two immiscible fluid phases within the QV600 chamber. For this ibu-SiO model, the 406 
moving mesh method was applied. COMSOL Multiphysics reports that this method provides the best results 407 
when tracking the interface between the phases is important, and also allows mass transport across the 408 
interface, which is difficult to implement using other methods (46). At 20µL/min, the flow entering the main 409 
  
chamber bounces of the bottom of the meniscus formed by the oil phase and creates a ripple in the main 410 
stream of flow. The interaction of the main stream of flow with the oil domain also creates very low velocity 411 
recirculating flow patterns within the oil which are separate to the main flow stream. The movement within 412 
the oil could be expected to have implications on the distribution of ibuprofen within the oil phase but it 413 
appears that, because the velocities are so low, the diffusion of the ibuprofen from the oil still occurs 414 
symmetrically, starting from the centre of the domain. As the inlet velocity increases, more asymmetrical 415 
diffusion patterns appear, but the recirculation velocities within the oil remain very low in comparison with 416 
the velocity observed in the main stream of flow, and so the distribution of ibuprofen in the oil domain 417 
appears to be controlled by the concentration gradient between the two phases. This is, in turn, controlled by 418 
the convection of ibuprofen away from the interface by the fluid flow. The flow profiles in the aqueous phase 419 
of the two phase model were not comparable with those seen in the dextran transport model. In that model, 420 
the membrane was modelled as a fluid matrix domain, whereby the fluid can move through the domain at a 421 
retarded rate based on the porosity and permeability of the membrane. For this reason, only a small 422 
percentage of fluid actually passes through the membrane and interacts with the donor domain. The majority 423 
of the flowing fluid sees this as a walled domain and so this reduces the height of the chamber, which is the 424 
reason for recirculating flows to develop instabilities. In the two-phase, oil/PBS model, the force of the 425 
aqueous flow is partially absorbed by the oil, which causes the recirculation within the oil, but also reduces 426 
the velocity of the aqueous flow in comparison with the single phase model. This reduction in velocity also 427 
removes the secondary recirculating streams which occur in the single phase model. 428 
As with the dextran transport simulations, the concentration of ibuprofen in the receptor domain was 429 
measured over time to validate the computer model of the ibu-SiO device within the QV600 chamber. The 430 
accuracy to which the model was able to predict the concentration of ibuprofen varied with the inlet flow 431 
rate. There is strong agreement in the trends between the experimental and simulated data (Figure 8), with 432 
the simulation able to predict the concentration of the ibuprofen in the receptor chamber over a period of 24 433 
hours. There are small discrepancies in the values of the Cmax at each flow rate, but the simulation is able to 434 
predict the total exposure of the ibuprofen in the bottom chamber to within 10%. At the highest flow rate, 435 
which is unrealistic in comparison with the in vivo environment, the Cmax was underestimated by the 436 
simulation, although the values for concentration under these conditions were at the very lower detection 437 
limit of the UV spectrophotometer. Furthermore, the differences in absolute value of Cmax were negligible in 438 
comparison to the 1mg/mL initial concentration present in the SiO. 439 
Computational models, such as the ones incorporating fluid dynamics, present the advantage of accurately 440 
describing the system behaviours when its constitutive parameters are varied. Unlike the traditional, 441 
benchtop experiments, after thorough validation and benchmarking, these models can be used to describe 442 
complex systems in a fast, inexpensive, accurate and reliable manner. Moreover, a vast parameter field can 443 
be tested and considered, enabling the analysis and comparison of different physical processes such as fluid 444 
flow or drug transport and diffusion.  445 
  
The fluid flow setup used in this study was designed to emulate the mechanism of elimination of molecules 446 
via convectional clearance analogous to the systemic circulation present in choroidal tissue in vivo. To 447 
validate the computer model, comparisons of the average concentration in the receptor compartment of the 448 
Kirkstall QV600 chamber were made between predicted and experimental data. It is important to note that 449 
previous studies have used computer models to study drug delivery and distribution in the posterior segment 450 
of the eye (29, 47, 48); these studies, however, are mostly theoretical or based on experimental data 451 
published by Palestine and Brubaker, who investigated the pharmacokinetics of fluorescein in the vitreous of 452 
humans (31). Our study looked to create an in silico model that could predict drug distributions in an in vitro 453 
model and that could be used in the development of a novel SiO-based drug delivery device. 454 
As robust and mathematically stringent as computer models may be, they will never be able to provide a 455 
fully accurate representation of a biological environment due to the variability and continually dynamic 456 
environment of nature. What they are able to do is provide predictions of results across a vast number of 457 
parameters in a fast and inexpensive manner. In terms of developing drug delivery devices such as the ibu-458 
SiO described here, it allows variations in conditions such as initial concentration, drug permeability and 459 
material properties, and produces estimations which can narrow the range of expensive and time-consuming 460 
experimental work that would otherwise need to be conducted. Ultimately, it would be of interest to apply 461 
the knowledge and understanding of drug release from SiO gained from these complementary in silico and in 462 
vitro models to build a computational model of the eye which could help us predict how this system might 463 
work in vivo in a human eye. 464 
Conclusion 465 
The ability to model drug transport across epithelial tissues such as the blood-retinal barrier could lead to the 466 
development of more effective treatments. The data presented here demonstrate the ability of in silico 467 
models to predict in vitro behaviour in complex environments. When used together, these complementary in 468 
vitro and in silico models could help make the design of drug delivery devices more efficient, as well as 469 
having potential benefits to the drug discovery community. Ophthalmologists and other researchers should 470 
be cautious when interpreting data from any model. No model will fully recapitulate the complex 471 
environment of the human eye, but more sophisticated designs that can reproduce features such as choroidal 472 
flow can help move experimental data closer to clinical behaviour. 473 
 474 
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Figure Legends 617 
Figure 1: Clearance mechanisms in the eye and comparison to Kirkstall QV600 system. (A) Key 618 
structures in the anterior and posterior drug clearance routes. Created with BioRender. The outer blood 619 
retinal barrier (OBRB) is the structure of interest in this study. (B, top) Schematic of Kirkstall QV600 set-up 620 
showing analogous OBRB structures (created with BioRender), (middle) dimensions of the QV600 chamber, 621 
(bottom) 3-dimensional composite of QV600 chamber. (C) Single pass experimental set-up. Dotted line 622 
represents dynamic flow. (a) Fresh media reservoir (b) QV600 chamber (c) peristaltic pump (d) waste 623 
collection reservoir. 624 
Figure 2: Input geometry and mesh generation of each model by COMSOL Multiphysics. (A) Input 625 
geometry for Kirkstall QV600 dextran simulations. Red dots indicate points 1 and 2 in grid independence 626 
study (B) Mesh generated for Kirkstall QV600 chamber used in dextran transport simulations. This mesh 627 
comprised 38,267 free triangular elements. (C,D) Geometry and mesh zoomed to membrane domain. (E) 628 
Input geometry, red dots indicate points 1 and 2 for grid independence study, and (F) mesh generated for 629 
Kirkstall QV600 chamber used in ibuprofen release simulations. This mesh comprised 2,258 free triangular. 630 
(G) Percentage difference in velocity at two points in the centre of the chamber compared with the finest 631 
mesh for dextran transport (finest mesh: 108,814 elements). (H) Percentage difference in velocity at two 632 
points in the centre of the chamber compared with the finest mesh ibuprofen release (finest mesh: 3481 633 
elements). An acceptable mesh density was deemed to produce <5% error.  634 
Figure 3: Steady-state velocity fields for different inlet flow rates used in the Kirkstall QV600 chamber 635 
geometry for dextran transport studies. Inlet flow rates: (A) 20µL/min, (B) 200µL/min, (C) 400µL/min 636 
and (D) 2mL/min. Colour scale bar indicates velocity (m/s). Streamlines show velocity field. Each flow rate 637 
shows areas of recirculating flow trapped in the corners of the receptor compartment on the inlet side which 638 
increase in size as the inlet flow rate is increased. The flow profile of the donor compartment becomes more 639 
uniform with increased flow rate.  640 
Figure 4: Concentration fields for different inlet flow rates used in the Kirkstall QV600 chamber 641 
geometry for dextran transport studies across acellular and seeded membranes at 1 hour. Colour scale 642 
bar indicates concentration (mol/m3). As expected, the drug is cleared from the donor chamber more rapidly 643 
as flow rate increases, but is impeded by the presence of cells. 644 
Figure 5: Experimental vs simulated average concentration profiles in the receptor compartment of 645 
the Kirkstall QV600 chamber for dextran transport studies across acellular and seeded membranes. 646 
Experimental data presented as mean concentration ± 1 SD, n = 3. There is good agreement with respect to 647 
the concentration at all flow rates, including the change of behaviours from burst release to exponential 648 
decay, with differences within 5% for acellular and 18% for cellular experiments.  649 
Figure 6: Deformation of the mesh. A steady-state solution is reached indicated by the meniscus formation 650 
at fluid-fluid interface boundary of the two phases (green boundary). 651 
  
Figure 7: Stead-state velocity (A) and concentration at 1 hour (B) fields for different inlet flow rates 652 
used in the Kirkstall QV600 chamber geometry for ibuprofen release studies. Inlet flow rates: 653 
20µL/min, 200µL/min and 2mL/min. (A) Colour scale bar indicates velocity (m/s), streamlines show 654 
velocity field. (B) Colour scale bar indicates concentration (mol/m3). The velocity simulation shows two 655 
distinct flow fields within each phase, with velocity within the oil phase being influenced by the flow in the 656 
fluid phase. This is accompanied by concentration contours that indicates that the fluid phase is influencing 657 
the concentration gradient in the oil phase. 658 
Figure 8: Experimental vs simulated average concentration profiles of ibuprofen in receptor 659 
compartment of Kirkstall QV600 chamber. Experimental data presented as mean concentration ± 1 SD, n 660 
= 3. There is good agreement with respect to the concentration at all flow rates, including the change of 661 
behaviours from burst release to exponential decay, with differences within 10%.  662 
 663 
  664 
  
Tables 665 
Table 1 - Input parameters for dextran transport studies 666 
Parameter Value 
Diffusion coefficient of FD in water  2.39 x10-11m2/s 
Diffusion coefficient of FD across ePTFE  1.2x10-6m2/s 
Diffusion coefficient of FD across ePTFE 
ARPE-19 complex 
1.1x10-7m2/s 
Initial concentration of FD in donor 
domain 
50 µg/mL 
Initial concentration of FD in membrane 
domain 
0 µg/mL 
Initial concentration of FD in receptor 
domain 
0 µg/mL 
Flow rate 20,200,400,2000 µL/min 
Permeability coefficient of ePTFE 1.4x10-5cm/s 
Permeability coefficient of ePTFE ARPE-
19 complex 
8.8x10-6cm/s 
Porosity of ePTFE membrane 0.3 (from manufacturer) 
Permeability of water across ePTFE 1x10-6cm2 
Density of water at 37°C 994.12 kg/m3  
Dynamic viscosity of water at 37°C 0.691 mPa.s 
 667 
Table 2 - Input parameters for ibuprofen release studies 668 
Parameter Value 
Diffusion coefficient of ibuprofen in 
1000c.st silicone oil 
3.35 x10-11 m2/s 
Diffusion coefficient of ibuprofen in 
water 
2.27 x10-13m2/s 
Partition coefficient of ibuprofen  2.2 (49) 
Initial concentration of ibuprofen in oil 
phase 
1 mg/mL 
Initial concentration of ibuprofen in 
aqueous phase 
0 µg/mL 
Flow rate 20, 200, 2000 µL/min 
Interfacial tension 1000c.st silicone 
oil/PBS 
50 mN/m (37) 
Wall contact angle of fluid interface 1.3 rad (38) 
Density of water at 37°C 994.12 kg/m3 
Dynamic viscosity of water at 37°C 0.691 mPa.s 
Density of silicone oil at 37°C 967 kg/m3 
Dynamic viscosity of silicone oil at 37°C 790 mPa.s 
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